SANES

8.934

+0.01%↑

BBVA

17.96

+0.62%↑

MUV2

531.2

-0.11%↓

INGA

21.545

+0.3%↑

KBC

105.2

+1.06%↑

SANES

8.934

+0.01%↑

BBVA

17.96

+0.62%↑

MUV2

531.2

-0.11%↓

INGA

21.545

+0.3%↑

KBC

105.2

+1.06%↑

SANES

8.934

+0.01%↑

BBVA

17.96

+0.62%↑

MUV2

531.2

-0.11%↓

INGA

21.545

+0.3%↑

KBC

105.2

+1.06%↑

SANES

8.934

+0.01%↑

BBVA

17.96

+0.62%↑

MUV2

531.2

-0.11%↓

INGA

21.545

+0.3%↑

KBC

105.2

+1.06%↑

SANES

8.934

+0.01%↑

BBVA

17.96

+0.62%↑

MUV2

531.2

-0.11%↓

INGA

21.545

+0.3%↑

KBC

105.2

+1.06%↑

Search

Sartorius Stedim Biotech.

Chiusa

SettoreFinanza

186.9 0.62

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

183.95

Massimo

187.85

Metriche Chiave

By Trading Economics

Entrata

-23M

93M

Vendite

400K

745M

P/E

Media del settore

69.871

28.864

EPS

0.94

Margine di Profitto

12.43

Dipendenti

10,134

EBITDA

-55M

201M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+23.55% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.4B

18B

Apertura precedente

186.28

Chiusura precedente

186.9

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 nov 2025, 23:07 UTC

Discorsi di Mercato

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20 nov 2025, 22:22 UTC

Discorsi di Mercato

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20 nov 2025, 22:08 UTC

Discorsi di Mercato

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20 nov 2025, 21:57 UTC

Utili

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20 nov 2025, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

20 nov 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

20 nov 2025, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

20 nov 2025, 21:50 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

20 nov 2025, 21:31 UTC

Utili

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20 nov 2025, 21:23 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20 nov 2025, 21:07 UTC

Utili

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 nov 2025, 21:06 UTC

Utili

Webull 3Q Rev $156.9M >BULL

20 nov 2025, 21:06 UTC

Utili

Webull 3Q EPS 7c >BULL

20 nov 2025, 21:05 UTC

Utili

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20 nov 2025, 21:04 UTC

Utili

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20 nov 2025, 21:04 UTC

Utili

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20 nov 2025, 21:04 UTC

Utili

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 nov 2025, 21:00 UTC

Utili

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20 nov 2025, 21:00 UTC

Utili

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20 nov 2025, 21:00 UTC

Utili

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20 nov 2025, 21:00 UTC

Utili

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20 nov 2025, 21:00 UTC

Utili

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20 nov 2025, 21:00 UTC

Utili

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20 nov 2025, 21:00 UTC

Utili

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20 nov 2025, 21:00 UTC

Utili

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20 nov 2025, 21:00 UTC

Utili

Intuit 1Q Consumer Rev $894M

20 nov 2025, 21:00 UTC

Utili

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20 nov 2025, 21:00 UTC

Utili

Intuit Backs FY26 Guidance

20 nov 2025, 21:00 UTC

Utili

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20 nov 2025, 21:00 UTC

Utili

Intuit 1Q Global Business Solutions Rev $3B

Confronto tra pari

Modifica del prezzo

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

23.55% in crescita

Previsioni per 12 mesi

Media 228.57 EUR  23.55%

Alto 246 EUR

Basso 210 EUR

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

5

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat